Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 6, 2015, Pages 544-563

  Younossi, Z M ^a   Park, H ^b   Saab, S ^c   Ahmed, A ^d   Dieterich, D ^e   Gordon, S C ^f  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MOUNT SINAI HOSPITAL   (United States)

^f HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; INTERFERON; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADULT; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG CAPSULE; DRUG COST; DRUG RESPONSE; EARLY INTERVENTION; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INCIDENCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; NONHUMAN; QUALITY ADJUSTED LIFE YEAR; TABLET; VIRUS LOAD; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; GENETICS; GENOTYPE; HEALTH CARE COST; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FLUORENES; GENOTYPE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 84922770382     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13081     Document Type: Article

References (73)

1. Wong JB, McQuillan GM, McHutchison JG, Poynard T,. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-9.
2. Gordon SC, Hamzeh FM, Pockros PJ, et al,. Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther 2013; 38: 784-93.
3. van der Meer AJ, Veldt BJ, Feld JJ, et al,. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
4. D'Ambrosio R, Aghemo A, Rumi MG, et al,. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56: 532-43.
5. Holmberg SD, Spradling PR, Moorman AC, Denniston MM,. Hepatitis C in the United States. N Engl J Med 2013; 368: 1859-61.
6. Moorman AC, Gordon SC, Rupp LB, et al,. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis 2013; 56: 40-50.
7. Stepanova M, Kanwal F, El-Serag HB, Younossi ZM,. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 2011; 53: 737-45.
8. McGowan CE, Monis A, Bacon BR, et al,. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 2013; 57: 1325-32.
9. Nguyen M,. Suboptimal treatment rates and treatment completion rates of chronic hepatitis C virus therapy in patients with comorbidities: analysis of a large real-world US cohort. Poster presented at the Liver Meeting: the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013. Washington, DC. Poster no. 2040.
10. Lam AM, Murakami E, Espiritu C, et al,. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother 2010; 54: 3187-96.
11. Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z,. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014; 40: 657-75.
12. Afdhal N, Reddy KR, Nelson DR, et al,. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
13. Afdhal N, Zeuzem S, Kwo P, et al,. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
14. Younossi ZM, Stepanova M, Henry L, et al,. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014; 12: 1349-59.
15. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al,. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21.
16. Feld JJ, Kowdley KV, Coakley E, et al,. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-603.
17. Hagan LM, Yang Z, Ehteshami M, Schinazi RF,. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat 2013; 20: 847-57.
18. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S,. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60: 530-7.
19. Deuffic-Burban S, Schwarzinger M, Obach D, et al,. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). J Hepatol 2014; 61: 7-14.
20. Recommendations for testing, managing, and treating hepatitis C, 2014. Available at: http://www.hcvguidelines.org/full-report-view (accessed 10 January 2015).
21. Kowdley KV, Gordon SC, Reddy KR, et al,. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
22. Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ,. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol 2012; 84: 1744-50.
23. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH,. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996; 125: 634-9.
24. Lawitz E, Lalezari JP, Hassanein T, et al,. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-8.
25. Rodriguez-Torres M, Rodriguez-Orengo J, Gagger A, et al,. Sofosbuvir and peginterferon alfa-2a/ribavirin for treatment-naïve genotype 1-4 HCV-infected patients who are coinfected with HIV. Poster presented at IDWeek 2013; October 2-6, 2013. San Francisco, CA. Poster no. 714.
26. Forns X, Lawitz E, Zeuzem S, et al,. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-79 e3.
27. Jacobson IM, Dore GJ, Foster GR, et al,. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-13.
28. Manns M, Marcellin P, Poordad F, et al,. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-26.
29. Reddy KT, Zeuzem S, Zoulim F, et al,. A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study in (APASL) 24th Conference of the Asian Pacific-Association for the Study of the Liver, 2014.
30. Lawitz E, Sulkowski MS, Ghalib R, et al,. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65.
31. Osinusi A, Meissner EG, Lee YJ, et al,. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804-11.
32. Naggie Sea. Sofosbuvir plus ribavirin for HCV genotype 1-3 infection in HIV coinfected patients (PHOTON-1) in CROI 2014. Conference on Retroviruses and Opportunistic Infections, 2014.
33. Sulkowski M,. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1,2, and 3 infection in patients co-infected with HIV (PHOTON-1). Oral presentation at the Liver Meeting: the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013a. Washington, DC. Presentation no. 212.
34. Ioannou GN, Beste LA, Green PK,. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clin Gastroenterol Hepatol 2014; 12: 1371-80.
35. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
36. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
37. Vierling JM, Davis M, Flamm S, et al,. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J Hepatol 2014; 60: 748-56.
38. Zein NN,. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13: 223-35.
39. Thein HH, Yi Q, Dore GJ, Krahn MD,. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31.
40. Dienstag JL, Ghany MG, Morgan TR, et al,. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011; 54: 396-405.
41. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y,. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158: 329-37.
42. Fattovich G, Giustina G, Degos F, et al,. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997; 27: 201-5.
43. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL,. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-65.
44. Liu J, Wang Y, Zhang D, Liu B, Ou Q,. Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. Eur J Gastroenterol Hepatol 2012; 24: 186-94.
45. Razavi H, Elkhoury AC, Elbasha E, et al,. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57: 2164-70.
46. Maylin S, Martinot-Peignoux M, Moucari R, et al,. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-9.
47. Poynard T, McHutchison J, Manns M, et al,. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
48. Pol S, Vallet-Pichard A, Corouge M,. Treatment of hepatitis C virus genotype 3-infection. Liver Int 2014; 34 (Suppl. 1): 18-23.
49. Mallet V, Gilgenkrantz H, Serpaggi J, et al,. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
50. Murphy K, Hoover DR, Shi Q, et al,. Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. AIDS 2013; 27: 2413-23.
51. Statistics BoL. Consumer Price Index. Washington, DC: Bureau of Labor Statistics, U.S. Department of Labor, 2014.
52. Redbook Online. Micromedex 2.0. Available at: http://micromedexsolutions.com (Accessed 5 January 2015).
53. Resource-Based Relative Values Scale (R-BRVS). The Essential RBRVS: A Comprehensive Listing of RBRVS Values for CPT and HCPCS Codes. Salt Lake City, UT, USA: Optum Insight Inc, 2014.
54. Gordon SC, Muir AJ, Lim JK, et al,. The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from HCV-TARGET Longitudinal Observational Study. Hepatology 2013; 58: 1104A.
55. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI,. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011; 17: 531-46.
56. Wright NM, Tompkins CN,. A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users. Harm Reduct J 2006; 3: 27.
57. Neumann PJ, Cohen JT, Weinstein MC,. Updating cost-effectiveness-the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014; 371: 796-7.
58. Briggs A, Claxton K, Sculpher M,. Decision Modelling for Health Economic Evaluation. New York, NY, USA: Oxford University Press, 2006.
59. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G,. Methods for the Economic Evaluation of Health Care Programmes. New York, NY, USA: Oxford University Press, 2005.
60. Gold MR, Siegel JE, Russel LB, Weinstein MC,. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
61. Jensen DM, O'Leary J, Pockros P, et al,. Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort. American Association For the Study Liver Disease (AASLD) conference oral presentation, November 7-11, 2014, Boston, MA.
62. Dugum M, O'Shea R,. Hepatitis C virus: here comes all-oral treatment. Cleve Clin J Med 2014; 81: 159-72.
63. Asselah T, Marcellin P,. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int 2014; 34 (Suppl 1): 60-8.
64. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM,. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol 2010; 8: 1017-29.
65. Berenguer J, Zamora FX, Carrero A, et al,. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis. J Acquir Immune Defic Syndr 2014; 66: 280-7.
66. Shev S, Dhillon AP, Lindh M, et al,. The importance of cofactors in the histologic progression of minimal and mild chronic hepatitis C. Liver 1997; 17: 215-23.
67. Freeman AJ, Law MG, Kaldor JM, Dore GJ,. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003; 10: 285-93.
68. Rusu E, Jinga M, Enache G, et al,. Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C-a randomized trial. Nutr J 2013; 12: 119.
69. Takase S, Tsutsumi M, Kawahara H, Takada N, Takada A,. The alcohol-altered liver membrane antibody and hepatitis C virus infection in the progression of alcoholic liver disease. Hepatology 1993; 17: 9-13.
70. Stroffolini T, Cotticelli G, Medda E, et al,. Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver Int 2010; 30: 867-70.
71. Bichoupan K, Martel-Laferriere V, Ng M, et al,. Real world costs of telaprevir-based triple therapy, including costs of managing adverse events, at the Mount Sinai Medical Center, NY: $195,000 per SVR12. Heptology 2013; 558: 329A-30A.
72. McLernon DJ, Dillon J, Donnan PT,. Health-state utilities in liver disease: a systematic review. Med Decis Making 2008; 28: 582-92.
73. Hsu PC, Federico CA, Krajden M, et al,. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol 2012; 27: 149-57.